# Monalizumab (Monalizumab) by AstraZeneca Pharmaceuticals LP: new bulk ingredient listing

**Launch Signal Score:** 15/100

| Field | Value |
|---|---|
| Generic name | Monalizumab |
| NDC | 0310-3333 |
| Labeler | AstraZeneca Pharmaceuticals LP |
| Product type | BULK INGREDIENT |
| Approval pathway | BULK INGREDIENT |
| Dosage form | LIQUID |
| Active ingredients | MONALIZUMAB 50 mg/50mg |
| Marketing start | 2026-07-13 |
| Package configurations | 1 |

## Why this score


Source: U.S. FDA National Drug Code (NDC) Directory via openFDA (https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=0310-3333). Last refreshed: 2026-11-03T18:09:00.764Z.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.